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Abstract
The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity
during development. Here we review a number of recent studies showing that HOX genes are strongly expressed
in ovarian cancer, and that in some cases the expression of specific HOX genes is sufficient to confer a particular
identity and phenotype upon cancer cells. We also review the recent advances in elucidating the different
functions of HOX genes in ovarian cancer. A literature search was performed using the search terms HOX genes
(including specific HOX genes), ovarian cancer and oncogenesis. Articles were accessed through searches
performed in ISI Web of Knowledge, PubMed and ScienceDirect. Taken together, these studies have shown that
HOX genes play a role in the oncogenesis of ovarian cancer and function in the inhibition of apoptosis, DNA repair
and enhanced cell motility. The function of HOX genes in ovarian cancer oncogenesis supports their potential role
as prognostic and diagnostic markers, and as therapeutic targets in this disease.
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Introduction
The HOX genes constitute a family of transcription fac-
tors that play key roles in embryonic development, espe-
cially in the patterning of the anterior to posterior axis,
from the level of the hindbrain to the end of the spine.
They are characterized by a highly conserved homeodo-
main region consisting of a 61-amino acid motif which
enables HOX proteins to bind to specific regions of
DNA in order to transcriptionally activate or repress
target genes. HOX proteins can function as monomers
or homodimers, although their target DNA binding affi-
nities and specificities are enhanced by functioning as
heterodimers or heterotrimers with members of the
three-amino acid loop extension (TALE) family of co-
factors, PBX and MEIS. HOX genes play fundamental
roles during embryonic development, controlling ante-
rior-posterior pattern formation, proliferation and differ-
entiation [1]. In adult tissue, HOX genes have been
implicated in a variety of biological pathways including
homeostasis, cell differentiation and the maintenance of
organ functioning [2].
In mammals, 39 HOX genes have been identified and
organised into 4 paralogous clusters (A, B, C and D)
located on 4 different chromosomes [3]. Each cluster
contains 9-11 genes aligning in 13 paralogue groups
based on homeobox sequence similarity and the position
within a cluster. In embryonic development each HOX
gene is expressed in a spatiotemporal pattern whereby
the position of the HOX gene within a HOX cluster cor-
responds to its order of expression along the anterior to
posterior axis. Thus for example, the 5’ genes (paralo-
gues 9-13) are involved in the differentiation of geni-
tourinary structures in the lumbosacral region. HOX
expression in adult tissues often reflects embryonic
expression, and different cancers show distinct changes
from normal adult expression [4]. These include tem-
porospatial deregulation where HOX gene expression in
a tumour of a specific tissue is temporospatially different
from the expression seen in the normal tissue, and/or
the increased expression of HOX genes that are usually
expressed at lower levels in the normal tissue. In addi-
tion, epigenetic changes can result in the down-regula-
tion or silencing of certain HOX genes which normally
function as tumour suppressors. Numerous studies have
demonstrated deregulated HOX gene expression in can-
cer including lung, prostate, breast, colon, bladder and
thyroid cancer [5-9] and also in ovarian cancer.
HOX genes and Ovarian Cancer
During development of the female reproductive system
four HOX genes, HOXA9, HOXA10, HOXA11, and
HOXA13 are expressed uniformly along the Müllerian
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duct axis, although in adults their expression becomes
spatially restricted to particular organs. HOXA9 becomes
expressed in the fallopian tubes, HOXA10 is expressed
in the developing uterus, HOXA11 in the lower uterine
segment and cervix and HOXA13 in the upper vagina
[10]. Their expression is thought to be important in pre-
serving a high level of developmental plasticity of the
female reproductive system due to the dramatic struc-
tural and functional changes which occur during the
oestrous cycle and pregnancy [10]. It is thought that
inappropriate expression of these genes is an early step
in epithelial ovarian neoplasia as they induce aberrant
epithelial differentiation. A study by Cheng et al. (2005)
[11] used immunohistochemical analysis of biopsied tis-
sue to show that the HOX genes which normally regu-
late Müllerian duct differentiation were not expressed in
normal ovarian surface epithelia (OSE) but were
expressed in epithelial ovarian cancers (EOCs). The
HOX expression pattern appears to determine the histo-
logical identity of EOCs with serous papillary, endome-
triod and mucinous tumours showing overexpression of
HOXA9, HOXA10 and HOXA11, respectively [11].
Another HOX gene, HOXA7, was reported to be aber-
rantly expressed both at the RNA level (by quantitative
PCR) and at the protein level (by immunohistochemistry
using an anti-HOXA7 antibody) in ovarian cancer
tissues which display Müllerian-like characteristics, how-
ever little or no expression was found in undifferen-
tiated ovarian carcinomas and normal OSE [12]. When
expressed ectopically in an undifferentiated ovarian
mouse tumour, HOXA7 was shown to promote the abil-
ity of HOXA9, HOXA10 and HOXA11 to induce Müller-
ian differentiation rather than induce lineage specificity
itself [11,12]. These results suggest HOXA7 plays a role
in epithelial differentiation of OSE in ovarian epithelial
cancers, although Ota et al. (2007) found HOXA7 over-
expression in all ovarian carcinomas tested, including
undifferentiated subtypes. This could suggest that
HOXA7 is associated with Müllerian differentiation but
is not sufficient to maintain it (Figure 1).
Several other studies have reported altered HOX gene
expression in ovarian carcinomas when comparing to
normal OSE [12-14] however, there are some discrepan-
cies. Naora et al. (2001) [15] found HOXB7 was
expressed at higher levels in ovarian carcinomas com-
pared to normal OSE. This was supported by a later
study by Yamashita et al. (2006) [13] who created an
expression profile of HOX genes in ovarian-derived
samples. In this study overexpression of 16 HOX genes
in ovarian cancer cell lines were found, the most com-
mon being HOXB7, HOXA13 and HOXB13. Overexpres-
sion varied between cell lines but of these 16 genes,
Figure 1 Role of HOX genes in ovarian cancer. A summary of the possible involvement of HOX genes in the cell biology of ovarian cancer
and their potential use as clinical markers for the disease. Up regulated genes are shown in green, down regulated genes are shown in red.
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HOXA10, A13, B4, B7, B13 and C13 showed little or no
expression in normal samples (Table 1). It should be
noted though that both of these studies examined the
expression of HOX genes at the RNA level only by
quantitative PCR.
Slightly different results were found in a more recent
study by Hong et al. (2010) [16]. In this study the
expression of 36 HOX genes in ovarian cancer cell lines
and tissues were compared to normal ovarian tissue,
revealing a difference in expression of 11 HOX genes
(HOXA7, B3, B4, B6, C10, C11, D1, D3, D10, D11 and
D13). Of these 11 genes, HOXB4 was the only HOX
gene showing significantly higher levels of expression in
ovarian cancer cell lines than in normal ovarian tissue
(p = 0.029). Its expression was confirmed at protein
level by Western blot analysis, with exclusive expression
in all 4 ovarian cancer cell lines and all 7 ovarian cancer
tissue samples and not in the normal ovarian tissues.
HOXB4 has also been implicated as a cancer-related
gene in other malignancies including breast cancer, leu-
kaemia, osteosarcoma and lung cancer [17-20].
Function of HOX genes in ovarian cancer
Tumour Growth
In addition to phenotypic determination, HOX genes are
thought to play a role in the oncogenesis of ovarian can-
cer. HOXB7 overexpression in immortalised OSE cells
was shown to upregulate basic fibroblast growth factor
(bFGF). bFGF is a potent mitogenic and angiogenic
factor, although in this study it should be noted that the
majority (95%) of bFGF protein was intracellular and a
relatively limited amount may therefore be available for
cell to cell signalling [15]. HOXB13 has also been shown
to enhance the proliferation of ovarian cancer cell lines
SKOV-3 and OVCAR5 in vivo, and to promote the
growth of a mouse ovarian cancer cell line in vivo and
in vitro [21]. This oncogenic function of HOXB13 is
thought to require activated ras, as HOXB13 promoted
tumourgenesis in ovarian cancer cell lines containing
genetic alterations in p53, myc and K-ras but not in cell
lines containing genetic alterations in p53, myc and Akt.
In this ras activated cell line, HOXB13 also conferred
resistance to tamoxifen-mediated apoptosis suggesting a
pro-survival role in ovarian cancer.
HOXA10 is also strongly expressed at the protein level
in ovarian clear cell adenoarcinomas (OCCA, 20/29
cases) [11,22] but not expressed in normal ovarian
epithelia, ovarian serous adenocarcinomas, or endome-
trial cysts [22]. When over expressed in the human
OCCA derived cell line ES-2, HOXA10 resulted in
increased proliferation, and a two-fold increase in cell
invasion as measured by a Matrigel invasion assay. Cor-
respondingly, its expression in tumour samples corre-
lates with poor survival. The 5-year survival rate in
patients with HOXA10 positive tumours was only 30%,
but it was 55.6% in the HOXA10 negative group [22].
Cell motility and spreading
In addition to promoting proliferation, HOXB7 and
HOXB13 are also thought to be associated with the
invasive characteristics of ovarian cancer cells. This
invasive ability was investigated in a study by Yamashita
et al. (2006) [13] using the invasive cancer cell line
SKOV-3, which overexpresses HOXB7 and HOXB13.
Antisense HOXB7 and HOXB13 fragments were intro-
duced into SKOV-3 cells which results in an 85% and
50% reduction of motility, respectively, suggesting a role
in cancer cell invasion. However, as invasion was not
completely suppressed the function of these HOX genes
may be redundant and complemented by closely related
genes such as HOXA13, which was also overexpressed
in this cell line.
Invasive EOC cell lines also show overexpression of
HOXA4 compared to non-invasive cell lines, suggesting
a possible role for HOXA4 in promoting migration and
invasion. However a number of studies have indicated
that the role of HOXA4 could be invasion-suppressive
as siRNA-mediated knockdown of HOXA4 enhanced
cellular motility in normal OSE cells treated with EGF
[23], although it had no affect on the basal levels of
migration in the absence of EGF. This finding was sup-
ported in part by Klausen et al. (2009) [24] where
knockdown of HOXA4 in OVCAR-3 and OVCAR-8
cells increased migration (although not Matrigel
Table 1 Over expression of HOX genes in ovarian cancer
cell lines using RT-PCR
Cell Line
HOX gene SKOV-3 CaOV3 JHOC-6 SMOV2 ES-2
A3 - - - 2.0 -
A4 - - - - 2.0
A7 - 2.1 - - -
A10 12.1 13.3 3.5 - 12.6
A13 > 300 > 300 > 300 > 300 > 300
B2 9.2 - - - 4.1
B3 6.6 - - - -
B4 267 44.9 - 141.8 91.8
B5 14.9 - - - -
B6 9.4 - - - -
B7 > 300 > 300 > 300 > 300 > 300
B8 47.6 - 3.2 - -
B9 6.1 3.1 3.0 5.6
B13 > 300 > 300 > 300 > 300 > 300
C13 - 3.3 - - -
D13 3.6 - - - -
Shows over expression of HOX genes in ovarian cancer cell lines by RT-PCR.
Numbers indicate folds of expression level of each HOX gene in cancer cells
compared with that in normal samples. After ref [13].
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invasion). HOXA4 knockdown also reduced cell-cell
adhesion and b1 integrin protein level within cell colo-
nies, suggesting b1 integrin has a role in mediating
these changes. Intriguingly, these changes in protein
level are not reflected at the RNA level, indicating that
the effect of HOXA4 on b1 integrin and hence cell moti-
lity may be through an indirect mechanism. Taken
together these findings suggest that HOXA4 is indeed
primarily a suppressor of invasion, and it is possible
then that the increased HOXA4 expression observed in
invasive cell lines may be linked to a tumour-suppres-
sive response.
DNA Repair
HOXB7 is one of the HOX genes which shows a mark-
edly higher expression in ovarian cancer cell lines com-
pared to normal ovarian epithelia [15] and promotes
growth in ovarian epithelial cells [11], but it also plays a
novel role in DNA double-strand break repair through
interacting with proteins that act as genomic caretakers,
including members of the DNA-dependent protein
kinase haloenzyme, Ku70, Ku80 and DNA-PKcs [25].
Binding of HOXB7 to such haloenzymes endogenously
and exogenously increased DNA repair through poly
(ADP) ribose polymerase (PARP) activity. Different
HOXB7 expressing breast cancer cell lines exposed to
ionising radiation (IR) showed enhanced end-joining
product formation and enhanced double-strand break
repair and non-malignant cell lines that were transfected
with a HOXB7 expression vector developed increased
resistance to killing by IR. Correspondingly, chromoso-
mal damage was reduced following IR and less residual
damage was seen in cells expressing HOXB7, an effect
which could be reversed by HOXB7 silencing. These
findings suggest that HOXB7 could be a potential target
for therapies that enhance IR cell killing.
Targeting HOX genes
As the function of the HOX genes is partly based on the
binding of HOX proteins to the TALE homeobox set of
co-factors, PBX and MEIS, the oncogenic features of the
aberrantly expressed HOX proteins could be impaired
by targeting these co-factors. PBX and MEIS have been
found extensively expressed both nuclear and cytoplas-
mically in ovarian carcinomas but only MEIS 1 and 2
are expressed in the nucleus of normal epithelia [26].
This suggests that these co-factors are important in
ovarian carcinogenesis most probably by potentiating
the function of aberrantly expressed HOX proteins.
A peptide called HXR9 has been designed to target
the interaction between HOX and PBX. This drug has
been shown to retard tumour growth and induce apop-
tosis in the ovarian cancer cell line SKOV-3 [27], a cell
line which shows highly deregulated expression of cer-
tain HOX genes. However, this effect was not seen in
the OV-90 cell line which does not show HOX gene
deregulation. HXR9 treatment has proven to be success-
ful in other malignancies showing HOX gene deregula-
tion including melanoma [28], myeloma [29], renal
cancer [30] and lung cancer [31]. These results show
that PBX/HOX binding is a potential target in ovarian
cancer.
HOX genes as potential biomarkers and prognostic
markers
Circulating autologous antibodies to tumour antigens
are potential diagnostic biomarkers for the detection of
early stage cancers. A systematic search for an ovarian
tumour antigen was undertaken by Naora et al (2001)
[15]. In this study, the SEREX methodology (serological
identification of antigens by recombinant expression
cloning) was used to screen tumour cDNA expression
libraries with ovarian cancer patient serum. HOXB7 was
one of the HOX genes found in this screen, with signifi-
cant serological reactivity to HOXB7 in 13 of the 39
ovarian cancer patients and in 1 healthy female, suggest-
ing the detection of anti-HOXB7 antibodies could act as
a possible diagnostic tool [13,15]. However, further
research using larger sample number sizes and correla-
tion studies of titre of anti-HOXB7 with disease stage is
needed. Similar methodology applied to the serum of
patients with serous ovarian carcinomas identified the
HOXA7 gene as a potential biomarker of this disease
[12], and HOXA10 as a promising prognostic marker for
OCCA as its over expression is strongly correlated with
poor survival and not expressed in normal OSE [22].
HOX genes showing markedly higher expression in
ovarian cancer cell lines and cancer tissue specimens
compared to the normal ovaries also have the potential
of acting as prognostic markers, these include HOXB4
[16] and HOXB7 [25]. In microarray analysis of ovarian
tissues, HOXA5 and HOXA9 were both shown to be
overexpressed [32]. HOXA5 has been found to act as a
tumour suppressor in breast tissue by transactivating
the p53 gene [7] to induce apoptosis by p53-dependent
and p53-independent mechanisms [33]. A possible
tumour-suppressor role for HOXA5 is also supported by
low HOXA5 expression in breast [7] and lung cancer
[34] tissues which is thought to be mediated by methy-
lation of the CpG island located on the 5’ end of the
HOXA5 gene [7].
In addition to expression profiling, epigenetic altera-
tions associated with ovarian carcinogenesis have been
studied [35-37]. The most common molecular alteration
in human neoplasia is DNA methylation [38] and this
could possibly act as a prognostic marker. Fiegl et al.
(2008) [39] analysed the DNA methylation of 71 genes
in 22 ovarian cancers and 18 non-neoplastic samples
and identified the best discriminators between cancer
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and non-neoplastic tissue as being HOXA10 and
HOXA11. In particular HOXA11 methylation was
strongly associated with poor outcome, suggesting a
possible role for DNA methylation as a prognostic mar-
ker in ovarian cancer. A more recent study has shown
that increased expression of HOXA10 is present in ovar-
ian carcinomas as a result of promoter hypomethylation
of HOXA10 [40]. This could also act as a prognostic fac-
tor in ovarian cancer as well as a possible therapeutic
target, for example by using drugs that can reverse epi-
genetic changes.
Conclusions
HOX gene function is associated with the oncogenesis
of ovarian cancer, having a proven role in proliferation,
cell migration and DNA repair, although the exact
mechanisms and pathways involved require further
study. Their oncogenic function together with the
observed differences in expression between normal
ovarian tissue and ovarian cancers suggest a potential
diagnostic and prognostic value for some HOX genes.
This potential is broad ranging as the oncogenic and/
or tumour suppressor functions of HOX genes indicate
numerous possible influences on the subtype of ovar-
ian cancer, its aggressiveness and the likelihood of
metastasis and angiogenesis, together with its response
to at least certain types of therapy, including radiother-
apy. The expression of individual HOX genes or groups
of HOX genes in tumours, circulating cells or cells in
the ascites, or the presence of HOX proteins in a
range of biological fluids are all potential sources of
valuable clinical information.
It is also apparent that HOX genes are potential thera-
peutic targets, as are the mechanisms which regulate
HOX protein function, such as the HOX/PBX heterodi-
mer which upon disruption has shown anti-tumour
effects in a variety of cancers [27,28,30,31]. These treat-
ments could be used alone or in combination with other
treatment modalities to increase tumour susceptibility;
for example treating ovarian tumours showing highly
elevated levels of HOXB7 with HXR9 could sensitise
cells to killing by ionising radiation. This approach may
also be valuable for treatment of drug-resistant cancers,
especially if HOX expression in the tumour indicates a
high level of HOX deregulation.
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